VALIANT (2025) — Trial Summary
VALIANT (2025): The VALIANT phase 3 trial evaluated pegcetacoplan, a targeted C3 complement inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), the largest trial conducted in these populations.
References
- Fakhouri F, Bomback AS, Ariceta G, et al. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025;393:2210-2220.